Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arm 1 MRI with gadolinium Clear all
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 24, 2026, 9:02 PM EDT
Completed No phase listed Observational

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 24, 2026, 9:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Molecular MRI of the Fibrotic Heart

NCT02012725
View directory record Official record
Conditions
Healthy, Myocardial Fibrosis, Chronic Kidney Disease
Interventions
Arm 1 MRI with gadolinium
Drug
Lead sponsor
Moriel Vandsburger
Other
Eligibility
20 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 24, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Diffusion MRI for Head and Neck Cancer

NCT04251481
View directory record Official record
Conditions
Head Cancer Neck
Interventions
PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 24, 2026, 9:02 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 24, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

NCT03588286
View directory record Official record
Conditions
Sudden Cardiac Death
Interventions
Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
Procedure · Other
Lead sponsor
Western Sydney Local Health District
Other
Eligibility
18 Years to 85 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 24, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport

NCT04046146
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Indocyanine Green, MultiSpectral Imaging System
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 24, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 24, 2026, 9:02 PM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 24, 2026, 9:02 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Upper Limb Spasticity

NCT02074150
View directory record Official record
Conditions
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00005065
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, motexafin gadolinium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 24, 2026, 9:02 PM EDT
Terminated Not applicable Interventional

Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma

NCT02584413
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Magnetic resonance imaging, Gadolinium contrast
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 7 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Improving the Concentration of MR Contrast in the Arteries

NCT02155218
View directory record Official record
Conditions
Magnetic Resonance Angiography, Contrast Media
Interventions
Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 24, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 24, 2026, 9:02 PM EDT